March Warning Letter Wednesday Recap: FDA Enforcement, QMSR, and the Future of Internal Audits

Warning Letter Wednesday Recap: March 2026

Hosted by Global Key Solutions | Open Q&A Forum

Every month, Global Key Solutions hosts Warning Letter Wednesday, a live session for pharmaceutical, biotech, and medical device quality and compliance professionals. This month we changed the format. Instead of a structured presentation, we ran an open Q&A forum, with a brief industry roundup to kick things off. Here is a recap of what we covered.

Warning Letter of the Month

KeyPedia, GKS's AI-powered regulatory intelligence platform, selected this month's warning letter from Omeo Private Limited, an Indian-based drug manufacturer cited by the FDA for significant CGMP violations.

The selection was not random. KeyPedia surfaces enforcement actions based on GXP and drug-related data, and this case fit a pattern that continues to show up in the numbers: foreign-based manufacturers, particularly those in India and China, appear disproportionately in FDA enforcement data relative to their domestic counterparts. For a deeper look at that trend, our recently published research paper in the Journal of Pharmaceutical Innovation, "The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014-2024," breaks down exactly how that gap has developed over the last decade.

Read the paper here: https://link.springer.com/article/10.1007/s12247-026-10406-3

Takeaways from the 50th Annual International GMP Conference

George Kwiecinski, CEO and Founder of GKS, attended the University of Georgia College of Pharmacy's 50th Annual International GMP Conference in Athens, GA earlier this month. Because the conference is run as a nonprofit, it draws significant FDA and ex-regulator participation, giving attendees a rare opportunity to hear directly from people inside the agency.

A few things stood out.

The "quality culture" framework is being retired.

For years, quality culture has been a go-to concept in the industry. Defining it, measuring it, building programs around it. The research that originally drove the concept has now largely sunset it. The reason: when quality is reduced to a set of KPIs and metrics, organizations optimize for the metrics rather than the underlying outcomes. That can actually leave a company worse off. The conversation is shifting toward quality management maturity and lean theory, frameworks rooted in systems thinking rather than compliance checkboxes.

One session went deep into the Toyota Production System as a foundation for this thinking, alongside the DOM framework (Design, Operation, Monitoring) and updated PIC/S guidance. The core idea is that durable quality comes from how systems are built and operated, not from how well teams hit quarterly targets.

FDA leadership weighed in on enforcement and organizational change.

Days two and three included speakers from FDA's Office of Pharmaceutical Quality, and the final day featured remarks from former FDA Commissioner Robert Califf. His comments ranged broadly across FDA's regulatory scope. He touched on the agency's reorganization, both the historical shift from district and field offices to its current structure, and the more recent move to the Office of Inspections and Investigations in 2024. Notably, generic drug manufacturing did not come up in the discussion, which Califf himself flagged as surprising.

QMSR: Now in Effect

As of February 2, 2026, the Quality Management System Regulation (QMSR) is an active enforcement tool. The QMSR harmonizes 21 CFR Part 820 with ISO 13485:2016, and the practical implications are still landing across the industry.

One implication that came up directly in the session: internal audit reports and management review meeting minutes are no longer off-limits to FDA investigators. Under QMSR, those documents can be reviewed during an inspection. Companies that have not thought carefully about how those records are written, maintained, and organized now have a reason to.

This was a central topic during our February Warning Letter Wednesday session as well. If you missed that one, the recording is available on our media page.

Is FDA's Warning Letter Process Actually Working?

This was one of the more direct conversations of the session. Warning letter volume has increased recently, but the harder question is whether the process is driving meaningful compliance change, or whether it has become a checkbox for the agency as much as for industry.

The concern is not new. The warning letter process was introduced to replace earlier enforcement mechanisms that were not producing results. The question being asked now is whether warning letters themselves have hit the same ceiling. Are companies taking them seriously? Is the FDA following through when responses fall short?

Layered on top of this is an institutional knowledge problem. Both the FDA and industry have lost significant expertise over the past several years through retirements and departures. A new generation of professionals is now making high-stakes decisions in real time, while also managing the introduction of AI, advanced manufacturing technologies, and regulatory frameworks that are still being written.

On Internal Audits

One of the sharper exchanges of the session was around internal audits and how most of them are run. The consensus: the majority of internal audit programs today are checkbox exercises. How many audits do we need to do this year? Who have we not visited in a while? Check, check, done.

The problem is that audits run without a clear purpose rarely produce meaningful corrective actions. A well-designed audit program starts with a question: what are we actually trying to learn from this? That means looking at a supplier's or function's historical performance before showing up, assigning the right auditor for what you are trying to find, and producing a report that senior leadership will actually read and act on.

The data in KeyPedia can support this kind of preparation. Reviewing a facility's FDA inspection history, warning letters, and observation trends before an audit gives quality teams a much more informed starting point than the SOP-driven calendar cycle most organizations default to.

What KeyPedia Showed During the Session

Throughout the Q&A, KeyPedia was used live to pull enforcement data and support the discussion. KeyPedia aggregates over 1.5 million FDA and global regulatory data points, including warning letters, inspections, recalls, and enforcement actions, and makes them searchable and analyzable for quality and compliance teams.

KeyPedia Lite, the free browse tier, is available now at globalkeysolutions.net/browse. For teams that want the full platform, including the Observation Agent, Legal module, and Investigator tools, you can request a demo at globalkeysolutions.net/request-demo.

Watch the Playback

Missed the live session? The full recording is available on our YouTube channel. Whether you want to catch the Q&A in full or revisit a specific topic, the timestamps are in the video description.

Join Us Next Month

Warning Letter Wednesday runs monthly. Each session is free and open to anyone in pharmaceutical, biotech, or medical device quality and compliance. In April, we will be joined by Anna Hanzlikova of A-Reg Solutions for a session on regulatory surveillance.

Details and registration: globalkeysolutions.net/media

Global Key Solutions builds KeyPedia, an AI-powered regulatory intelligence platform for pharmaceutical, biotech, and medical device quality and compliance teams.